Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
New England Journal of Medicine · 08.06.2023 · 388 (23) · 2159-2170
DOI: 10.1056/nejmoa2302312 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 08.06.2023. Verfasst von Ramez N Eskander und 26 weiteren Autor:innen. Beteiligte Einrichtung: From the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Diego, Rebe…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Endometrial Neoplasms. Die Arbeit wurde bisher 787-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIEHS NIH HHS, National Cancer Institute.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: Standard first-line chemotherapy for endometrial cancer is paclitaxel plus carboplatin. The benefit of adding pembrolizumab to chemotherapy remains unclear. METHODS: In this double-blind, placebo-controlled, randomized, phase 3 trial, we assigned 816 patients with measurable disease (stage III or IVA) or stage IVB or recurrent endometrial cancer in a 1:1 ratio to receive pembrolizumab or placebo along with combination therapy with paclitaxel plus carboplatin. The administration of pembrolizumab or placebo was planned in 6 cycles every 3 weeks, followed by up to 14 maintenance cycles every 6 weeks. The patients were stratified into two cohorts according to whether they had mismatch repair-deficient (dMMR) or mismatch repair-proficient (pMMR) disease. Previous adjuvant chemotherapy was permitted if the treatment-free interval was at least 12 months. The primary outcome was progression-free survival in the two cohorts. Interim analyses were scheduled to be triggered after the occurrence of at least 84 events of death or progression in the dMMR cohort and at least 196 events in the pMMR cohort. RESULTS: In the 12-month analysis, Kaplan-Meier estimates of progression-free survival in the dMMR cohort were 74% in the pembrolizumab group and 38% in the placebo group (hazard ratio for progression or death, 0.30; 95% confidence interval [CI], 0.19 to 0.48; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Diego, Rebecca and John Moores Cancer Center, La Jolla (R.N.E.), and the Kaiser P…
ORCID-Profile: Richard G Moore
Förderung
- NCI NIH HHS
- NIEHS NIH HHS
- National Cancer Institute
- Merck & Co., Inc.
Zitieren
APA
Eskander, R. N., Sill, M. W., Beffa, L., Moore, R. G., Hope, J. M., Musa, F. B., Mannel, R., Shahin, M. S., Cantuaria, G. H., Girda, E., Mathews, C., Kavecansky, J., Leath, C. A., Gien, L. T., Hinchcliff, E. M., Lele, S. B., Landrum, L. M., Backes, F., O'Cearbhaill, R. E., …, & Aghajanian, C. (2023). Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. New England Journal of Medicine, 388(23), 2159-2170. https://doi.org/10.1056/nejmoa2302312
Vancouver
Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, et al. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. New England Journal of Medicine. 2023;388(23):2159-2170. doi:10.1056/nejmoa2302312
BibTeX
@article{Eskander2023,
author = {Eskander, Ramez N and Sill, Michael W and Beffa, Lindsey and Moore, Richard G and Hope, Joanie M and Musa, Fernanda B and Mannel, Robert and Shahin, Mark S and Cantuaria, Guilherme H and Girda, Eugenia and Mathews, Cara and Kavecansky, Juraj and Leath, Charles A and Gien, Lilian T and Hinchcliff, Emily M and Lele, Shashikant B and Landrum, Lisa M and Backes, Floor and O'Cearbhaill, Roisin E and Al Baghdadi, Tareq and Hill, Emily K and Thaker, Premal H and John, Veena S and Welch, Stephen and Fader, Amanda N and Powell, Matthew A and Aghajanian, Carol},
title = {Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer},
journal = {New England Journal of Medicine},
year = {2023},
volume = {388},
number = {23},
pages = {2159--2170},
doi = {10.1056/nejmoa2302312}
}
EUVIMED